What is the main business of Cardiac Development?

The main business activity of Cardiac Development focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 26, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Józefa I Jana Rostafińskich 4, 02-593 Warszawa.

Who is on the management board?

The management board consists of: Andrzej Jan Białkowski Miler (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.

What revenue was generated?

In 2023, the company generated total revenue of $1, representing an increase of 400.0% compared to 2022.

No, in 2023 the company was not profitable, reporting a net loss of $1,742. For comparison, in 2022 the loss was $4,219, meaning the company reduced its loss by 61.1%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $550 in 2023, representing 100% of all operating expenses.

Cardiac Developmentsp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-05-26

Share capital

5,000.00 PLN

Registered address

ul. Józefa I Jana Rostafińskich 4, 02-593 Warszawa, Poland

Financials

Revenue history

Filing timeliness

No financial statement for 2024 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 976 days for 2021).

2024not filed
202317/03/2025
202217/03/2025
202117/03/2025
202029/07/2021
201916/10/2020

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2023.

Results vs industry

Revenue

This companyUSD 1.19MedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -1.74kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 550.42MedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 2.74kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Andrzej Białkowski Miler – President of the Management Board

Manner of representation

Each member of the management board independently.

Ownership

Owner	Shares	Share value	Stake
Simplicardiac sp. z o.o.	100	$1,350.62	100%

Beneficial owners

No beneficial owners recorded for the company Cardiac Development.

Bank accounts

Was a VAT taxpayer from 2018-08-26 to 2025-09-26.

Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Bioselsp. z o.o.	$19,100.32	selol.pl
Omnisepticasp. z o.o.	$3,475.29	omniseptica.com
Wavex Energysp. z o.o.	$142.33	wavexenergy.com